vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and BingEx Ltd (FLX). Click either name above to swap in a different company.
BingEx Ltd is the larger business by last-quarter revenue ($143.2M vs $85.1M, roughly 1.7× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 2.2%, a 20.6% gap on every dollar of revenue.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
FDMT vs FLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $143.2M |
| Net Profit | $19.4M | $3.2M |
| Gross Margin | — | 10.8% |
| Operating Margin | 17.3% | — |
| Net Margin | 22.8% | 2.2% |
| Revenue YoY | 8508900.0% | — |
| Net Profit YoY | 139.1% | — |
| EPS (diluted) | $0.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.2M | ||
| Q4 25 | $85.1M | — | ||
| Q3 25 | $90.0K | $141.2M | ||
| Q2 25 | $15.0K | $143.0M | ||
| Q1 25 | $14.0K | $141.0M | ||
| Q4 24 | $1.0K | — | ||
| Q3 24 | $3.0K | $164.6M | ||
| Q2 24 | $5.0K | — |
| Q1 26 | — | $3.2M | ||
| Q4 25 | $19.4M | — | ||
| Q3 25 | $-56.9M | $6.1M | ||
| Q2 25 | $-54.7M | $7.5M | ||
| Q1 25 | $-48.0M | $27.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-43.8M | $3.4M | ||
| Q2 24 | $-35.0M | — |
| Q1 26 | — | 10.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.1% | ||
| Q2 25 | — | 12.0% | ||
| Q1 25 | — | 10.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 11.3% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 17.3% | — | ||
| Q3 25 | -67983.3% | 1.4% | ||
| Q2 25 | -396373.3% | 1.9% | ||
| Q1 25 | -383007.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1704400.0% | 4.0% | ||
| Q2 24 | -849120.0% | — |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 22.8% | — | ||
| Q3 25 | -63195.6% | 4.4% | ||
| Q2 25 | -364386.7% | 5.2% | ||
| Q1 25 | -342657.1% | 19.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1461433.3% | 2.1% | ||
| Q2 24 | -699060.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | $0.43 | — | ||
| Q3 25 | $-1.01 | — | ||
| Q2 25 | $-0.98 | — | ||
| Q1 25 | $-0.86 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.79 | — | ||
| Q2 24 | $-0.63 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $561.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | — |
| Total Assets | $566.7M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $561.1M | ||
| Q4 25 | $402.7M | — | ||
| Q3 25 | $305.1M | $628.6M | ||
| Q2 25 | $293.2M | $499.4M | ||
| Q1 25 | $321.4M | $592.4M | ||
| Q4 24 | $424.9M | — | ||
| Q3 24 | $501.9M | $517.4M | ||
| Q2 24 | $541.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $505.7M | — | ||
| Q3 25 | $369.0M | — | ||
| Q2 25 | $420.9M | — | ||
| Q1 25 | $469.7M | — | ||
| Q4 24 | $510.6M | — | ||
| Q3 24 | $552.9M | — | ||
| Q2 24 | $588.3M | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $566.7M | — | ||
| Q3 25 | $424.0M | $1.3B | ||
| Q2 25 | $473.6M | $1.2B | ||
| Q1 25 | $515.7M | $1.2B | ||
| Q4 24 | $560.4M | — | ||
| Q3 24 | $604.0M | $926.8M | ||
| Q2 24 | $620.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | — |
| Free Cash FlowOCF − Capex | $28.5M | — |
| FCF MarginFCF / Revenue | 33.5% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.6M | — | ||
| Q3 25 | $-46.5M | — | ||
| Q2 25 | $-43.4M | — | ||
| Q1 25 | $-47.8M | — | ||
| Q4 24 | $-134.6M | — | ||
| Q3 24 | $-29.4M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $28.5M | — | ||
| Q3 25 | $-46.6M | — | ||
| Q2 25 | $-43.4M | — | ||
| Q1 25 | $-48.4M | — | ||
| Q4 24 | $-138.4M | — | ||
| Q3 24 | $-31.2M | — | ||
| Q2 24 | $-30.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 33.5% | — | ||
| Q3 25 | -51765.6% | — | ||
| Q2 25 | -289620.0% | — | ||
| Q1 25 | -345635.7% | — | ||
| Q4 24 | -13837100.0% | — | ||
| Q3 24 | -1038966.7% | — | ||
| Q2 24 | -611840.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 101.1% | — | ||
| Q2 25 | 440.0% | — | ||
| Q1 25 | 4507.1% | — | ||
| Q4 24 | 378600.0% | — | ||
| Q3 24 | 59266.7% | — | ||
| Q2 24 | 6980.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
